Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Fr | Vaxil Bio Ltd: Vaxil Bio's proposed RTO with Green Date terminated | 1 | Stockwatch | ||
Do | Vaxil Bio Ltd.: Vaxil Bio Proposed Reverse Takeover With Green Date Terminated | 55 | GlobeNewswire (Europe) | Not for distribution to United States newswire services or for release publication, distribution or dissemination directly, or indirectly, in whole or in part, in or into the United States NESS-ZIONA... ► Artikel lesen | |
21.08.24 | Vaxil Bio Ltd: Vaxil Bio firms up RTO with Green Data Center | 1 | Stockwatch | ||
21.08.24 | Vaxil Bio Ltd.: Vaxil Bio Enters Into Definitive Agreement With Green Data Centers for Reverse Take Over | 163 | GlobeNewswire (Europe) | Not for distribution to United States newswire services or for release, publication, distribution or dissemination directly, or indirectly, in whole or in part, in or into the United States. Any failure... ► Artikel lesen | |
27.05.24 | Vaxil Bio Ltd.: Vaxil Bio Enters Into Letter of Intent With Green Data in Respect of A Proposed Reverse Takeover | 1.815 | GlobeNewswire (Europe) | Not for distribution to United States newswire services or for release publication, distribution or dissemination directly, or indirectly, in whole or in part, in or into the United States TORONTO... ► Artikel lesen | |
VAXIL BIO Aktie jetzt für 0€ handeln | |||||
04.03.24 | Vaxil Bio Ltd.: Vaxil Bio Proposed Reverse Takeover with Copper Bullet Terminated and Update of Research Activities | 635 | GlobeNewswire (Europe) | Not for distribution to United States newswire services or for release publication, distribution or dissemination directly, or indirectly, in whole or in part, in or into the United States NESS-ZIONA... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
QIAGEN | 44,935 | +0,65 % | EQS-Adhoc: QIAGEN N.V.: QIAGEN zahlt rund 300 Millionen Dollar durch einen synthetischen Aktienrückkauf an seine Aktionärinnen und Aktionäre zurück | EQS-Ad-hoc: QIAGEN N.V. / Schlagwort(e): Aktienrückkauf
QIAGEN N.V.: QIAGEN zahlt rund 300 Millionen Dollar durch einen synthetischen Aktienrückkauf an seine Aktionärinnen und Aktionäre zurück... ► Artikel lesen | |
KEROS THERAPEUTICS | 10,860 | +3,04 % | Deep Dive Into Keros Therapeutics Stock: Analyst Perspectives (11 Ratings) | ||
BIONTECH | 109,20 | +0,18 % | BioNTech Aktie testet Widerstände: Kommt der nächste Ausbruch? | Die BioNTech Aktie befindet sich in einer spannenden charttechnischen Phase mit einem NASDAQ-Schlusskurs vom Freitag bei 122,85 US-Dollar und einer insgesamt positiven Entwicklung seit Mitte des Jahres.... ► Artikel lesen | |
EVOTEC | 7,990 | +3,30 % | Evotec, flatexDEGIRO, Hypoport, K+S, Puma, United Internet u.a. - Aktien-Positionen der Short-Seller | Wer Aktien leerverkauft, also auf fallende Kurse spekuliert (Shortselling), unterliegt bestimmten Transparenzpflichten. Aktuelle Meldungen über Leerverkäufe geben Aufschluss darüber. Diese Vorgaben... ► Artikel lesen | |
NURIX THERAPEUTICS | 19,140 | -1,80 % | Nurix Therapeutics, Inc. - 8-K, Current Report | ||
TEMPUS AI | 35,150 | +1,15 % | Tempus AI Inc (TEM): AI-Driven Healthcare Revolution | ||
SUMMIT THERAPEUTICS | 19,020 | +4,56 % | Looking At Summit Therapeutics' Recent Unusual Options Activity | ||
AVIDITY BIOSCIENCES | 28,905 | +2,35 % | Avidity Biosciences, Inc. (RNA): The Biotech Stock with Biggest Upside Potential | ||
ADMA BIOLOGICS | 16,000 | -3,79 % | ADMA BIOLOGICS, INC. - 8-K, Current Report | ||
DAY ONE BIOPHARMACEUTICALS | 12,540 | +1,13 % | Day One Biopharmaceuticals, Inc. - 8-K, Current Report | ||
SPRINGWORKS THERAPEUTICS | 34,590 | -2,81 % | Rappta Therapeutics enters into a global license agreement with SpringWorks Therapeutics for a pre-clinical first-in-class molecular glue targeting PP2A | Goal to accelerate development and commercialization of the lead asset RPT04402 for the treatment of a subset of uterine cancersFinancials include a $13 million upfront payment and potential... ► Artikel lesen | |
RECURSION PHARMACEUTICALS | 6,525 | +1,95 % | Recursion Pharmaceuticals, Inc. (RXRX): Revolutionizing Drug Discovery with AI and Strategic Collaborations for Strong Growth | ||
SANA BIOTECHNOLOGY | 3,160 | -2,77 % | Sana Biotechnology (NASDAQ:SANA) Stock Price Down 5.5% - What's Next? | ||
MOONLAKE IMMUNOTHERAPEUTICS | 43,900 | +5,86 % | MoonLake upgraded at Goldman Sachs on promise of hidradenitis suppurativa asset | ||
DYNE THERAPEUTICS | 14,120 | -4,30 % | Dyne Therapeutics Reports Positive Data From ACHIEVE Study Of DYNE-101 In Myotonic Dystrophy Type 1 | WASHINGTON (dpa-AFX) - Dyne Therapeutics, Inc. (DYN) Friday announced encouraging data from its ongoing Phase 1/2 ACHIEVE trial of DYNE-101 in patients with myotonic dystrophy type 1 (DM1).... ► Artikel lesen |